Journals / Respiratory Case Reports / 2015 / Cilt: 4 - Sayı: 1

Genç Yaşta Görülen Malign Plevral Mezotelyoma Olgusu

Pages
29–33
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, mesothelioma should be considered in the case of malignant pleural effusion and detailed immunostaining should be performed in order to ascertain the diagnosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Malignant mesothelioma is a tumor with poor prog- nosis that usually occurs 20-40 years after asbestos exposure.
📊
Key Findings & Data:Here, we present a 27-year-old patient with malignant pleural mesothelioma who did not report any asbestos exposure.
💡
Conclusion & Impact:In conclusion, mesothelioma should be considered in the case of malignant pleural effusion and detailed immunostaining should be performed in order to ascertain the diagnosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Malignant mesothelioma is a tumor with poor prog- nosis that usually occurs 20-40 years after asbestos exposure. Here, we present a 27-year-old patient with malignant pleural mesothelioma who did not report any asbestos exposure. A female non-smoker was admitted with complaints of chest pain and dyspnea. The physical examination revealed dullness with percussion in the right lower lobe. There was a free-flowing pleural effusion through the right middle zone and bilaterally nodular opacities in chest x-ray. The ADA level, ARB and mycobacterium culture of the pleural fluid were negative. There were some malignant cells in the cytological examination of the fluid, and therefore the primary site of malignancy was evaluated. Thoracoscopy revealed nodular tu- moral infiltration in the parietal pleura and thickness of the visceral layer. The pathological examination and immunostaining of the biopsy specimens were reported as biphasic malignant mesothelioma. In conclusion, mesothelioma should be considered in the case of malignant pleural effusion and detailed immunostaining should be performed in order to ascertain the diagnosis.

Özet

Malign mezotelyoma asbest temasından 20-40 yıl sonra ortaya çıkan, prognozu kötü bir tümördür. Burada 27 yaşında, bilinen asbest teması olmayan bir malign plevral mezotelyoma olgusu sunulmuştur. Sigara öyküsü olmayan bayan hasta nefes darlığı ve yan ağrısı ile başvurdu. Fizik muayenede, sağ alt zonda matite tespit edilen hastanın akciğer grafisinde sağda orta zona kadar uzanan serbest plevral efüz- yon ve her iki akciğerde multipl, nodüler dansiteler saptandı. Plevral sıvı incelemesinde hemorajik karak- terde eksüdatif efüzyon izlendi. Plevral sıvın ADA seviyesi, ARB ve mikobakteri kültürü negatif bulundu. Sıvı sitolojisi malignite açısından kuşkulu bulunan hastada primer odak araştırması yapıldı. Hastaya torakoskopi planlandı, pariyetal plevrada lokal tümör odakları, visseral plevrada kalınlaşma gözlendi. Bi- yopsi örneklerinin patoloji ve immün boyama sonuç- ları bifazik malign mezotelyoma olarak raporlandı. Sonuç olarak, malign plevral efüzyon varlığında me- zotelyoma olasılığı göz ardı edilmemeli ve tanıyı ke- sinleştirmek için ayrıntılı immünohistokimyasal ince- leme yapılmalıdır.

🔖

Cite This Article

BAŞYİĞİT, İ., BOYACI, H., KUŞCU, E. U., YILDIZ, K., AKGÜL, A. G., BARIŞ, S. A., YILDIZ, F. (2015). Genç Yaşta Görülen Malign Plevral Mezotelyoma Olgusu. Respiratory Case Reports, Cilt: 4 - Sayı: 1, 29–33. https://ajindex.com/articles/302489

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Arslan S. Malign plevral mezoteyoma. In: Yücel O, Genç O, eds. Plevra hastalıkları ve tedavisi. Ankara: Derman Tıbbi Yayıncılık; 2011:45-50
  2. Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002; 26:55-65. [CrossRef] 3. Wagner JC. Mesothelioma and mineral fibers. Cancer 1986; 57:1905-11. [CrossRef] 4. Gün S, Kandemir B, Kefeli M, Yıldız L, Barış S, Karagöz F. The role of D2-40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. Turk J Pathol 2010; 26:189-95. [CrossRef] 5. Kawashima A, Libshitz HI, Lukeman JM. Radiationinduced malignant pleural mesothelioma. Can Assoc Radiol J 1990; 41:384-6
  3. Bech C, Sørensen JB. Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome. J Thorac Oncol 2008; 3:1359-60. [CrossRef] 7. Livasy CA, Tishko DJ, Maygarden SJ. Miliary pulmonary metastases from a clinically occult pleural mesothelioma. Ann Diagn Pathol 2003; 7:249-53. [CrossRef] 8. Khan AN, Al-Jahdali HH, Allen CM, Irion KL, Al Ghanem S, Koteyar SS. The calcified lung nodule: What does it mean? Ann Thorac Med 2010; 5:67-79. [CrossRef] 9. Light RW. Tumors of the pleura. In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine, vol 2. Philadelphia: Saunders; 1994:2222-30
  4. Metintaş M. Mezotelyoma. In: Göksel T, Özlü T, eds. Akciğer ve plevra maligniteleri tedavisi. Ankara: Poyraz Tıbbi Yayıncılık; 2008:78-111
  5. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95. [CrossRef] 12. Elkiran ET, Kaplan MA, Sevinc A, Aksoy S, Demirci U, Seker M, et al. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol 2012; 29:3147-54. [CrossRef] 13. Metintaş M, Metintaş S, Uçgun İ, Gibbs AR, Harmanci E, Alatas F, et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 2001; 95:829-35. [CrossRef]